PB 49 of 2016
National Health (Originator Brand) Amendment Determination 2016 (No. 4)
National Health Act 1953
I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.
Dated 30 May 2016
_____________________________________
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health
(1) This Determination is the National Health (Originator Brand) Amendment Determination 2016 (No. 4).
(2) This Determination may also be cited as PB 49 of 2016.
This Determination commences on 1 June 2016.
3 Amendments to PB 100 of 2015
Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).
Schedule 1 Amendments
(section 3)
[1] Schedule 1 (table item 1)
Repeal the item, substitute:
1 | Acarbose | Glucobay 50 Glucobay 100 |
|
|
1A | Aciclovir | Zovirax Zovirax 200 mg Zovirax 800 mg |
|
|
[2] Schedule 1 (after table item 18)
Insert:
18A | Azacitidine | Vidaza |
|
|
[3] Schedule 1 (after table item 74)
Insert:
74A | Eplerenone | Inspra |
|
|